Literature Scan

Literature Scan

New and noteworthy research from the medial literature landscape

Long-Term Follow-Up Confirms Safety, Efficacy of Imatinib for CML

Early results (published in Leukemia in 2009) from the phase III International Randomized Study of Interferon and STI571 (IRIS) demonstrated that imatinib 400 mg...

Deep Response With Venetoclax Plus Rituximab in Relapsed/Refractory CLL

Combining the selective BCL2 inhibitor venetoclax with rituximab may increase the depth and durability of response in patients with relapsed/refractory chronic lymphocytic leukemia (CLL),...

Aplastic Anemia Nearly Triples Risk of VTE

The systemic inflammation that characterizes aplastic anemia (AA) may also contribute to a greater risk of venous thromboembolism (VTE), giving patients with AA a...

Idelalisib Combination Improves PFS But Increases Infection Risk in Relapsed/Refractory CLL

According to a randomized, placebo-controlled, phase III study published in the Lancet Oncology, adding idelalisib to the combination of bendamustine and rituximab (BR) nearly...

AML and Other Myeloid Neoplasms According to WHO A Look at the Revised Classification

In June 2016 the World Health Organization (WHO) updated its 2008 classification of tumors of the hematopoietic and lymphoid tissues. The revised myeloid disorders...

Rivaroxaban Beats Aspirin in Reducing Risk of Recurrent VTE, Even at Lower Doses

Patients with venous thromboembolism (VTE) require anticoagulation, but concerns about bleeding have complicated decisions about using higher- or lower-intensity anticoagulation or aspirin for subsequent...

Identifying Genetic Mutations That Can Predict Transplant Outcome in Patients With Myelodysplastic Syndromes

Though allogeneic hematopoietic cell transplantation (alloHCT) is the only curative option for myelodysplastic syndromes (MDS), transplant-related mortality, complication rates, and available, suitable donors preclude...

Efficacy of Eltrombopag in Patients With Lower-Risk Myelodysplastic Syndromes and Thrombocytopenia

Platelet transfusions are commonly administered to patients with myelodysplastic syndromes (MDS) who develop profound thrombocytopenia, but the short therapeutic effect and eventual transfusion refractoriness...

POT-KAST and POT-CAST: Questioning Routine Thromboprophylaxis After Casting or Knee Surgery

The value of prescribing thromboprophylaxis to prevent venous thromboembolism (VTE) after knee arthroscopy or casting of the lower leg is debatable, and the risk−benefit...

Lenalidomide Maintenance Therapy Related to More Secondary Primary Malignancies in Older Adults

Results from the Myeloma XI trial presented at the 2016 ASH Annual Meeting supported the use of lenalidomide as maintenance therapy for patients with...
Advertisement

Current Issue

May 2017, Volume 3, Issue 6

This issue discusses the legacy of Agent Orange and hematologic malignancies, a debate over transplant in myelodysplastic syndromes, and more.